CDCP Antibodies

Santa Cruz Biotechnology provides a broad selection of CDCP Antibodies for advanced research in cell biology and cancer studies. Monoclonal CDCP Antibodies demonstrate high effectiveness in various applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). The CUB domain-containing protein 1 (CDCP1) plays a crucial role in cell adhesion, migration, and signaling, making it an important target in cancer research. CDCP1 is often overexpressed in various tumors and is associated with poor prognosis, highlighting its significance in understanding tumor progression and metastasis. By studying CDCP1, researchers can gain insights into potential therapeutic targets and strategies for cancer treatment. CDCP1 research has revealed important mechanisms in tumor cell survival and metastatic potential. Understanding CDCP1 expression patterns helps identify new approaches for targeted cancer therapies. Ongoing studies of CDCP1 continue to uncover its complex roles in cancer development and progression. Santa Cruz Biotechnology monoclonal CDCP Antibodies support researchers worldwide in advancing cancer biology knowledge and developing innovative therapeutic strategies.